Company Filing History:
2 out of 8 
2 out of 8 Years Active: 2018-2020
Title: Manuel Grez: Innovator in Cancer Immunotherapy
Introduction
Manuel Grez is a prominent inventor based in Heidelberg, Germany. He has made significant contributions to the field of cancer immunotherapy, particularly through his innovative work with NK-92 cells. With a total of 2 patents, Grez is recognized for his advancements in targeted cell therapeutic agents.
Latest Patents
Grez's latest patents focus on CAR-expressing NK-92 cells as cell therapeutic agents. The inventions relate to an ErbB2-specific NK-92 cell or cell line that contains a lentiviral vector encoding a chimeric antigen receptor. This technology is designed to target ErbB2-expressing cancers, providing a method for prevention and treatment. The patents also detail methods for generating and identifying these specific NK-92 cells, emphasizing their potential use in adoptive cancer immunotherapy.
Career Highlights
Throughout his career, Grez has worked with notable organizations, including the Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus and the DRK Blutspendedienst Baden-Württemberg-Hessen GmbH. His work in these institutions has furthered research in cancer treatment and therapeutic applications.
Collaborations
Grez has collaborated with esteemed colleagues such as Winfried Wels and Kurt Schonfeld. These partnerships have contributed to the advancement of his research and the development of innovative therapeutic strategies.
Conclusion
Manuel Grez stands out as a key figure in the field of cancer immunotherapy, with his innovative patents and collaborative efforts paving the way for future advancements in targeted therapies. His work continues to inspire and influence the landscape of cancer treatment.